Starting Sooner, Targeting Lower: How Updated ACC/AHA Guidelines Redefine Lipid-Lowering Strategy

The 2026 update to the ACC/AHA guideline for dyslipidemia management represents a meaningful shift in how and when clinicians should begin lipid-lowering therapy, Erin D. Michos, MD, MHS, professor of medicine, director of Women's Cardiovascular Health and associate director of Preventive Cardiology in the Division of Cardiology at Johns Hopkins University School of Medicine, explains.

Central to the new guidance is the principle that "lower LDL for longer" reduces cumulative cardiovascular risk—a concept analogous to pack-years of smoking exposure. In practice, this means treating patients sooner, even those at lower short-term risk, if their lifetime burden of atherogenic particles is projected to be high.

The updated guideline adopts the new PREVENT-ASCVD calculator, which offers several advantages over the older Pooled Cohort Equations. Derived from a more diverse, multiethnic population, PREVENT incorporates kidney function and social determinants of health for more precise risk estimation. Crucially, it extends risk estimation to patients as young as age 30 and provides both 10-year and 30-year risk projections—enabling clinicians to identify younger patients who may appear low-risk in the short term but carry significant lifetime risk. The new threshold for a class I statin indication is 5% 10-year risk, down from the prior 7.5%; borderline-risk patients (3-5%) with risk-enhancing factors also warrant statin consideration.

Equally important, the guideline restores explicit LDL-C targets—a move clinicians and patients alike will find actionable. For very high-risk patients with established atherosclerotic cardiovascular disease (ASCVD), the target is LDL below 55 mg/dL (with an apolipoprotein B target below 55 mg/dL). Because most patients cannot reach this goal with statins alone, the guideline embraces combination therapy. Non-statin agents—including ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran—now carry robust outcome data and are positioned as essential tools alongside statins. Clinicians are encouraged to think in terms of where a patient's LDL is starting and which combination of therapies will most efficiently close the gap to a risk-based target.